Milwaukee Institute for Drug Discovery
The Milwaukee Institute for Drug Discovery (MIDD) was established to advance research and later-stage development of new drugs from research at the University of Wisconsin-Milwaukee and collaborating institutions. The Institute will focus on several areas of research strength at UWM; with initiatives in neuroscience, cancer, and infectious diseases. Because of the cross-functional nature of drug discovery and development, the MIDD is focused on collaborations among UWM departments, regional and national academic centers, and medical product companies.
Key Elements of the MIDD Mission
- Support exploratory research in focus therapeutic areas
- Conduct pre-clinical and clinical studies leading to Proof-of-Concept
- Provide project management, regulatory, CM&C, clinical design, and logistical expertise
for development projects
- Form research and product development collaborations
- Work closely with the UWM Research Foundation on patenting and licensing
- Enhance educational opportunities through curriculum and fellowship programs
- Develop linkages to the greater UWM community and promote regional economic development
Several Department of Chemistry and Biochemistry faculty were awarded grants from SE Wisconsin Applied Chemistry Center of Excellence.
-Alexander (Leggy) Arnold received $84,346 to develop and commercialize a universal kinase and GTPase assay.
-Peter Geissinger received a $84,823 grant to develop optical sensors for real-time effluent monitoring of waste water treatment systems.
-Graham Moran is developing known drug and herbicide targets as commercial products. The amount awarded was $50,492.
-Nicholas Silvaggi was received a $56,670 grant to manipulating the immune response focusing on the enhanced prediction of protease cleavage sites.
-Jörg Woehl received a $100,000 grant to develop a prototyping platform for accelerated chemical analysis and drug discovery at the single molecule level.